A
0.011
0.00 (0.00%)
| Previous Close | 0.011 |
| Volume | 101,340 |
| Price / Sales | 1.08 |
| Price / Book | 4.55 |
| 52 Weeks Range |
| Operating Margin (TTM) | -4,310.00% |
| Diluted EPS (TTM) | -0.020 |
| Quarterly Revenue Growth (YOY) | -97.30% |
| Total Debt/Equity (MRQ) | 61.92% |
| Current Ratio (MRQ) | 1.92 |
| Operating Cash Flow (TTM) | -4.27 M |
| Levered Free Cash Flow (TTM) | -4.06 M |
| Return on Assets (TTM) | -60.07% |
| Return on Equity (TTM) | -132.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | ACRUX FPO [ACR] | - | - |
AIStockmoo Score
-0.9
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | -0.93 |
|
Acrux Ltd is a dynamic Australian drug delivery specialist with expertise in developing and commercialising patient-preferred healthcare products for world-wide markets. Its talent creates value through the development and commercialisation of healthcare products using owned or acquired technologies. The group's products are patient preferred, protected by patent or other means, and use creative drug delivery. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 17.06% |
| % Held by Institutions | 9.98% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |